Biomarkers of Histone Deacetylase Inhibitor Activity in a Phase 1 Combined-Modality Study with Radiotherapy

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair

(2013) B Groselj et al.   BRITISH JOURNAL OF CANCER

Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation

(2013) Mo Li et al.   CANCER CELL

A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

(2013) B. Venugopal et al.   CLINICAL CANCER RESEARCH

ERCC1, MLH1, MSH2, MSH6, and βIII-Tubulin: Resistance Proteins Associated With Response and Outcome to Platinum-based Chemotherapy in Malignant Pleural Mesothelioma

(2013) Saskia Ting et al.   Clinical Lung Cancer

DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors

(2013) Toshio Hirohata et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Design and conduct of early-phase radiotherapy trials with targeted therapeutics: Lessons from the PRAVO experience

(2013) Anne Hansen Ree et al.   RADIOTHERAPY AND ONCOLOGY

MYC Regulation of CHK1 and CHK2 Promotes Radioresistance in a Stem Cell-like Population of Nasopharyngeal Carcinoma Cells

(2012) W.-J. Wang et al.   CANCER RESEARCH

SirT1 regulates radiosensitivity of hepatoma cells differently under normoxic and hypoxic conditions

(2012) Yuexia Xie et al.   CANCER SCIENCE

The histone deacetylase SIRT2 stabilizes Myc oncoproteins

(2012) P Y Liu et al.   CELL DEATH AND DIFFERENTIATION

Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group

(2012) Winnie Yeo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer

(2012) David R. Jones et al.   Journal of Thoracic Oncology

Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP

(2012) A Bangert et al.   ONCOGENE

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma

(2012) Marie Saelen et al.   Radiation Oncology

Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

(2011) B. Ramaswamy et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

(2011) L. Kretzner et al.   CANCER RESEARCH

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

(2011) Omar Khan et al.   IMMUNOLOGY AND CELL BIOLOGY

Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic

(2011) Jacob E. Shabason et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation

(2011) Sung-Keum Seo et al.   Journal of Thoracic Oncology

Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress

(2011) Ira Tabas et al.   NATURE CELL BIOLOGY

Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma

(2011) Prakash Chinnaiyan et al.   NEURO-ONCOLOGY

Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy

(2011) Åse Bratland et al.   Radiation Oncology

Tumor Cell Kill by c-MYC Depletion: Role of MYC-Regulated Genes that Control DNA Double-Strand Break Repair

(2010) K. R. Luoto et al.   CANCER RESEARCH

A therapeutic role for targeting c-Myc/Hif-1- dependent signaling pathways

(2010) Klaus Podar et al.   CELL CYCLE

Therapeutic Targeting of the DNA Mismatch Repair Pathway

(2010) S. A. Martin et al.   CLINICAL CANCER RESEARCH

An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

BRCA1 16 years later: nuclear import and export processes

(2010) Marilyn E. Thompson   FEBS Journal

Prediction of Response to Preoperative Chemoradiotherapy in Rectal Cancer by Multiplex Kinase Activity Profiling

(2010) Sigurd Folkvord et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Histone Deacetylase Inhibitors: The Epigenetic Therapeutics That Repress Hypoxia-Inducible Factors

(2010) Shuyang Chen et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc

(2010) Caihua Zhu et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study

(2010) Anne Hansen Ree et al.   LANCET ONCOLOGY

Mismatch-repair protein MSH6 is associated with Ku70 and regulates DNA double-strand break repair

(2010) Ankita Shahi et al.   NUCLEIC ACIDS RESEARCH

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents

(2010) M. Namdar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

(2010) O. Khan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Essential Role of the HIF-1α-c-Myc Axis in Malignant Progression

(2009) Young-Gun Yoo et al.   Annals of the New York Academy of Sciences

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

(2009) Susan Fotheringham et al.   CANCER CELL

Radiosensitization by SAHA in Experimental Colorectal Carcinoma Models—In Vivo Effects and Relevance of Histone Acetylation Status

(2009) Sigurd Folkvord et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines

(2008) Paul Noordhuis et al.   BIOCHEMICAL PHARMACOLOGY

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells

(2008) A. Scuto et al.   BLOOD

ElevatedFOSB-expression; a potential marker of valproate sensitivity in AML

(2008) Farhat L. Khanim et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting tumor angiogenesis with histone deacetylase inhibitors

(2008) Leigh Ellis et al.   CANCER LETTERS

Carrot and stick: HIF-α engages c-Myc in hypoxic adaptation

(2008) L E Huang   CELL DEATH AND DIFFERENTIATION

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

HDAC2 deficiency and histone acetylation

(2008) Anne Hansen Ree et al.   NATURE GENETICS

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

(2008) Da Wei Huang et al.   NUCLEIC ACIDS RESEARCH

Hypoxia Causes Downregulation of Mismatch Repair System and Genomic Instability in Stem Cells

(2008) Francisco Javier Rodríguez-Jiménez et al.   STEM CELLS